Benefits

Joint Health

Supports symptoms of mild to moderate osteoarthritis*
‍
Supports joint function*
‍
Supports joint stiffness*
‍
Supports joint comfort*
‍

Levagen^® demonstrated dose-dependent improvement (300mg & 600mg) in WOMAC scores* (discomfort, stiffness and function) compared to the placebo in the management of mild to moderate osteoarthritis (Steels et al. 2019).

‍

Levagen^® offers morning and evening joint ache reduction when compared to placebo over a 14 day period, suggesting that PEA may be a beneficial and effective treatment for joint pain.* (Briskey, et al. 2021)

Sleep

Levagen^®+ was shown to reduce anxiety* and improve QOL* (Rao et al. 2021), providing PEA's relevance and application in sleep.

PEA is part of the extended endocannabinoid family, thus may promote restful sleep through indirect activation of the calm-inducing CB1 receptors (Costa et al. 2008). It can also increase restful REM sleep by activating TRPV1 channels* (Petrosino et al. 2015).

To learn more about the use of PEA as an alternative to CBD see NotCBD

Sports Performance & Recovery

Human clinical study by (Mallard et al. 2020) demonstrates the benefits of Levagen^®+ for:

Recovery · Significantly reduces levels of myoglobin* (a marker for muscle damage) and stimulates the Akt/PkB pathway* (downstream region of the mTOR pathway involved in muscle protein synthesis).

‍Performance · Significantly reduces lactate levels, allowing to exercise at higher intensities and/or for a longer duration*.

Please fill out a contact form to request access to our Sports Nutrition White Paper.

Immune Health

PEA has been shown to optimize the immune system* and provide symptomatic relief of flu symptoms* (Hesselink et al. 2013). This is due to unique actions on numerous pathways, such as activation of PPAR-a and inhibiting mast cell degranulation (Petrosino 2015).

To learn more about PEA's immune-boosting mechanisms, please fill out the contact form below to request access to our PEA and Immunity White Paper.

Discomfort and Inflammation

Levagen^®+ was proven to reduce diabetic peripheral neuropathic pain* and inflammation* over an 8 week period. (Pickering, et al. 2022)

PEA offers a variety of benefits and has been studied as an alternative to traditional NSAIDS for pain*. Levagen^®+ resolved significant headaches*and headache symptoms* faster than a traditional NSAID, without accentuating side effects. (Briskey, et al. 2022)

Cognitive Health

In a brand new study, Levagen^®+ efficacy was studied at 700mg or a matching placebo for 6 weeks in a double armed, cross-over trail.

Levagen^®+ supported significant improvement in serum BDNF levels when compared to placebo and helped to improve memory through better first success and fewer errors. (Kim et al. 2024)

‍

Skin Health

Levagen^®+ was shown to significantly reduce skin dryness and redness, and reduced a total POEM score in a topical formulation applied twice daily for 4 weeks. (Rao, et al. 2024)

‍

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This material is educational in nature and is not intended to serve as regulatory and/or legal advice.

Not all claims made are valid in all global regions.

Gencor

Home